NCT04976270

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of GLPG3667 in Adult, Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is a phase I, randomized, double-blind, placebo-controlled, single-center, to evaluate the safety, tolerability, and pharmacokinetics (PK) of GLPG3667 after an oral single dose (SD) of GLPG3667 (part 1) and after oral multiple doses (MD) for 13 days of GLPG3667 (part 2) in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG3667	GLPG3667 capsules
DRUG	Placebo	Matching placebo capsules

Timeline

• Start date: 2021-07-20
• Primary completion: 2022-01-14
• Completion: 2022-01-14
• First posted: 2021-07-26
• Last updated: 2022-02-14

Locations

1 site across 1 country: Belgium